BR112021009225A2 - Análogos de gdf15 e métodos para uso na diminuição do peso corporal e/ou na redução da ingestão de alimentos - Google Patents

Análogos de gdf15 e métodos para uso na diminuição do peso corporal e/ou na redução da ingestão de alimentos Download PDF

Info

Publication number
BR112021009225A2
BR112021009225A2 BR112021009225-0A BR112021009225A BR112021009225A2 BR 112021009225 A2 BR112021009225 A2 BR 112021009225A2 BR 112021009225 A BR112021009225 A BR 112021009225A BR 112021009225 A2 BR112021009225 A2 BR 112021009225A2
Authority
BR
Brazil
Prior art keywords
dose
administered
day
fusion protein
study
Prior art date
Application number
BR112021009225-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Songmao Zheng
Holly Kimko
Robert Hermann
Elisa Fabbrini
Vedrana Stojanovic-Susulic
Paul Rothenberg
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112021009225A2 publication Critical patent/BR112021009225A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BR112021009225-0A 2018-11-20 2019-11-19 Análogos de gdf15 e métodos para uso na diminuição do peso corporal e/ou na redução da ingestão de alimentos BR112021009225A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769675P 2018-11-20 2018-11-20
US62/769,675 2018-11-20
PCT/IB2019/059945 WO2020104948A1 (en) 2018-11-20 2019-11-19 Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake

Publications (1)

Publication Number Publication Date
BR112021009225A2 true BR112021009225A2 (pt) 2021-10-05

Family

ID=70773869

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021009225-0A BR112021009225A2 (pt) 2018-11-20 2019-11-19 Análogos de gdf15 e métodos para uso na diminuição do peso corporal e/ou na redução da ingestão de alimentos

Country Status (15)

Country Link
US (1) US20220315633A1 (https=)
EP (1) EP3883960A4 (https=)
JP (2) JP2022513098A (https=)
KR (1) KR20210094584A (https=)
CN (2) CN113474363A (https=)
AU (2) AU2019383019A1 (https=)
BR (1) BR112021009225A2 (https=)
CA (1) CA3120236A1 (https=)
EA (1) EA202191424A1 (https=)
IL (1) IL283189A (https=)
JO (1) JOP20210111A1 (https=)
MX (1) MX2021005908A (https=)
PH (1) PH12021551119A1 (https=)
SG (1) SG11202104952PA (https=)
WO (1) WO2020104948A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP4041281B1 (en) 2019-10-04 2025-11-26 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9131966B2 (en) * 2013-03-11 2015-09-15 DePuy Synthes Products, Inc. Vertebral manipulation assembly
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
JP6946304B2 (ja) * 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
EA202191105A1 (ru) * 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение

Also Published As

Publication number Publication date
JOP20210111A1 (ar) 2021-05-19
CN121818901A (zh) 2026-04-10
AU2019383019A1 (en) 2021-06-03
KR20210094584A (ko) 2021-07-29
JP2022513098A (ja) 2022-02-07
EP3883960A4 (en) 2022-11-09
WO2020104948A1 (en) 2020-05-28
MX2021005908A (es) 2021-09-08
PH12021551119A1 (en) 2021-11-22
AU2025202337A1 (en) 2025-04-24
US20220315633A1 (en) 2022-10-06
JP2025081388A (ja) 2025-05-27
EA202191424A1 (ru) 2021-08-24
IL283189A (en) 2021-06-30
EP3883960A1 (en) 2021-09-29
SG11202104952PA (en) 2021-06-29
CA3120236A1 (en) 2020-05-28
CN113474363A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
JP6333775B2 (ja) インスリングラルギンの長時間作用型製剤
ES3037632T3 (en) A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia
TW201201832A (en) Pharmaceutical composition comprising AVE0010 and insulin glargine
ES2949095T3 (es) Formulación de relación fija de insulina glargina/lixisenatida
ES2895513T3 (es) Tratamiento con lixisenatida de pacientes pediátricos con diabetes mellitus tipo 2
JP2025081388A (ja) 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法
JP7389862B2 (ja) 成長ホルモン欠乏症の検出および治療
US20220323550A1 (en) Pegloticase for treatment of gout in renal transplant recipients
JP2022512632A (ja) 発作性夜間ヘモグロビン尿症（ｐｎｈ）の処置のための抗ｃ５抗体の皮下投薬及び投与
JP2008518941A (ja) 大腸連続性を伴う短腸症候群患者の治療
US9814761B2 (en) Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders
Quagliata et al. Therapeutic applications of thymosin peptides: a patent landscape 2018-present
CA2782838A1 (en) Bche albumin fusions for the treatment of cocaine abuse
JP2023544832A (ja) １型糖尿病の治療および予防のための方法および組成物
Moretz Orphan Drug Evaluation: Myalept®(metreleptin) subcutaneous injection
CARE Approach to the Identification and Differentiation of Migraine
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
WO2019032469A1 (en) TREATMENT OF OVERWEIGHT AND OBESITY ASSOCIATED WITH LEPTIN IMPAIRMENT
Herring Insulin Detemir Compared to NPH insulin: A Study to Explore whether Differences Exist between Glucose Flux, Lipolysis, Pharmacokinetics and Brain Function during Hyperglycaemia in Type 1 Diabetes
ACE Glycemic Targets for Nonpregnant Adults
Harris CLINICAL PROTOCOL APPROVAL FORM
BR112017015099B1 (pt) Uso de lixisenatida e/ou um sal farmaceuticamente aceitável da mesma para tratar pacientes pediátricos portadores de diabetes mellitus tipo 2